Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s rezpegaldesleukin in atopic dermatitis – AD ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...

Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 13 cents. In the year-ago quarter, the ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports.